COHANCE
OVERVALUEDCohance Lifesciences Limited
Pharma · NSE
↓ 223.0% vs fair value
52W Low
₹267
+14.6% from low
52W High
₹1,123
-72.8% from high
Valuation Gauge
Current Price
₹306
Fair Value
₹95
Fair Value Analysis
₹95
Based on free cash flow projections and earnings growth potential for Pharma sector companies | CAUTION: ROCE declining (latest 19.0%) — returns on capital are falling; verify this isn't a value trap. | Growth capped at 7.8% (ROE 6.8%×1.15) — historical CAGR exceeds sustainable rate or COVID period unverifiable.
Cash Flow Analysis
38% weight
Growth Valuation
63% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Solid Fundamentals
Profitability
ROE of 6.8% is below the Pharma sector benchmark of 18%
Debt & Leverage
D/E ratio of 0.1x is well within the Pharma sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 34.6x is slightly below the Pharma sector median of 42x — reasonably valued
Cash Flow
FCF margin of 11.3% — strong cash generation (₹132 Cr)
Earnings Growth
5yr EPS CAGR of -16.1% — earnings are declining (sector avg growth: 15.3%)
Dividend
No dividend — typical for growth-stage companies
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
0.4%
Free cash flow / market cap
Revenue Growth (YoY)
-19.4%
Year-on-year revenue change
Profit Growth (YoY)
-81.0%
Year-on-year PAT change
Operating Cash Flow
₹288 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹8.9
P/E Ratio
34.6x
P/B Ratio
2.5x
ROE
6.8%
ROCE
13.3%
Debt / Equity
0.11x
Beta
0.16
Div Yield
—
FCF (Cr)
₹132 Cr
Revenue (Cr)
₹1,172 Cr
EPS Growth 5Y
-16.1%
Mkt Cap (Cr)
₹11,766 Cr
52W High
₹1,123.4
52W Low
₹266.7
Book Value/Share
₹125.4
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹2.5K Cr | ₹558 Cr | 22.0% | ₹259 Cr | ₹8.91 |
| 2025-03-31 | ₹1.2K Cr | ₹375 Cr | 31.0% | ₹265 Cr | ₹10.52 |
| 2024-03-31 | ₹1.1K Cr | ₹406 Cr | 39.0% | ₹300 Cr | ₹11.80 |
| 2023-03-31 | ₹1.3K Cr | ₹574 Cr | 43.0% | ₹411 Cr | ₹16.16 |
| 2022-03-31 | ₹1.3K Cr | ₹582 Cr | 44.0% | ₹454 Cr | ₹17.83 |
| 2021-03-31 | ₹1.0K Cr | ₹443 Cr | 44.0% | ₹362 Cr | ₹14.23 |
| 2020-03-31 | ₹834 Cr | ₹385 Cr | 46.0% | ₹317 Cr | ₹12.45 |
| 2019-03-31 | ₹378 Cr | ₹172 Cr | 45.0% | ₹109 Cr | — |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Pharma| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Par Drugs And Chemicals Limited | ₹86 | ₹469.7 | +81.7% | 7.3 | 15.4% | FAIRLY_VALUED |
IOL Chemicals and Pharmaceuticals Limited | ₹79.5 | ₹237.8 | +66.6% | 19.6 | 5.2% | FAIRLY_VALUED |
Kilitch Drugs (India) Limited | ₹132.7 | ₹321 | +58.7% | 17.7 | 9.4% | UNDERVALUED |
Bal Pharma Limited | ₹69 | ₹147.5 | +53.2% | 12.8 | 12.6% | FAIRLY_VALUED |
Zydus Lifesciences | ₹868 | ₹1,502.2 | +42.2% | 17.6 | 19.9% | UNDERVALUED |
Natco Pharma | ₹1,030 | ₹1,597 | +35.5% | 11.8 | 18.0% | UNDERVALUED |
Jagsonpal Pharmaceuticals Limited | ₹190.6 | ₹275.2 | +30.7% | 30.8 | 20.1% | UNDERVALUED |
Lupin | ₹2,280 | ₹3,112 | +26.7% | 22.4 | 23.8% | UNDERVALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Company Documents
Annual reports, concall transcripts & regulatory filings
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant